𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Plasma exchange removes glycosphingolipid in Fabry disease

✍ Scribed by Pyeritz, Reed E. ;Ullman, M. David ;Moser, Ann B. ;Braine, Hayden G. ;Moser, Hugo W. ;Optiz, John M.

Publisher
John Wiley and Sons
Year
1980
Tongue
English
Weight
393 KB
Volume
7
Category
Article
ISSN
0148-7299

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Diclofenac, paracetamol, and vidarabine
Diclofenac, paracetamol, and vidarabine removal during plasma exchange in polyarteritis nodosa patients
✍ F. Fauvelle; P. Nicolas; A. Leon; M. Tod; G. Perret; O. Petitjean; L. Guillevin πŸ“‚ Article πŸ“… 1991 πŸ› John Wiley and Sons 🌐 English βš– 564 KB

## Abstract Since plasma exchange (PE) represents a major treatment for patients suffering from systemic diseases, its influence on the kinetics of three drugs was investigated: vidarabine, used in patients with polyarteritis nodosa associated with hepatitis B virus (eight subjects), and diclofenac

Use of plasma exchange in methotrexate r
Use of plasma exchange in methotrexate removal in a patient with osteosarcoma and acute renal insufficiency
✍ Karin Zattar Cecyn; Juno Lee; Tsutomo Oguro; AntΓ΄nio SΓ©rgio Petrilli; JosΓ© Orlan πŸ“‚ Article πŸ“… 2003 πŸ› John Wiley and Sons 🌐 English βš– 69 KB πŸ‘ 1 views

## Abstract Acute renal failure induced by methotrexate (MTX) can be lethal because renal excretion of the drug can be delayed. Pre‐existing renal impairment, abstention, or underdosage of folinic acid and inadequate hydration facilitate toxicity. The prolonged high serum levels of MTX result in se

Analysis of venous access for therapeuti
Analysis of venous access for therapeutic plasma exchange in patients with neurological disease
✍ J. E. Grishaber; M. C. Cunningham; P. A. Rohret; R. G. Strauss πŸ“‚ Article πŸ“… 1992 πŸ› John Wiley and Sons 🌐 English βš– 446 KB

We retrospectively analyzed our 2-year experience with venous access for 363 therapeutic plasma exchanges in 46 patients with neurological disease, including acute Guillain-Barrd syndrome (N = 20). myasthenia gravis (N = 17), and chronic inHammatory demyelinating polyneuropathy (N = 9). Twenty-three